Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
TheraCryf logo — company profile

TheraCryf

Founded 2007 United Kingdom Wilmslow, United Kingdom 9 employees Post-IPO Equity Total: $12.46M Biotechnology, Pharmaceutical

General Information

Company Name TheraCryf
Founded Year 2007
Location United Kingdom Wilmslow, United Kingdom
Employees 9
Industries Biotechnology, Pharmaceutical
Funding Stage Post-IPO Equity
Business Model B2B, B2D
Revenue Model Licensing, Performance Based, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with TheraCryf. To contact TheraCryf, visit theracryf.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About TheraCryf

TheraCryf is a clinical-stage therapeutics company, strategically positioning itself at the forefront of innovation in oncology and behavioral brain disorders. Originally known as Evgen Pharma plc, the company's recent acquisition of Chronos Therapeutics in April 2024 has broadened its mission and enhanced its portfolio, leading to its rebranding as TheraCryf.

The company's pivotal clinical asset, SFX-01, is a patented sulforaphane-based medicine. TheraCryf also benefits from Chronos' neuropsychiatry assets which employ novel chemistry with strong intellectual property protection. Their expertise in developing and commercializing these therapeutics positions them as a potential partner for mid-size to large pharma companies.

Founded in 2007 and headquartered in the United Kingdom, TheraCryf attracted a £10.00M Post-IPO Equity investment in February 2021, showcasing strong interest from investors in the biotechnology and pharmaceutical sectors.

Taxonomy: Clinical stage drug development, Cancer treatment, Neurological disease treatment, Sulforadex® technology, Sulforaphane analogues, Medical potential, Peer-reviewed scientific papers, Therapeutic compounds, Biopharmaceutical, Clinical research, Commercial product development

Services & Products

Drug Discovery
Pre-clinical Development
Clinical Collaboration
Regulatory Submissions

Target Customers

Mid-size to Large Pharmaceutical Companies Patients with Brain Disorders Healthcare Providers Scientific Research Institutions

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity £10.00M -
03 Feb 2021
Venture Round $2.00M 2
Acceleris Capital Seneca Partners
Acceleris Capital, Seneca Partners
10 Sep 2015
Venture Round £460.00K 3
Enterprise Ventures The North West Fund
Enterprise Ventures, The North West Fund +1
25 Jul 2012
Series A Undisclosed 2
The North West Fund Rising Stars Growth Fund
The North West Fund, Rising Stars Growth Fund
20 Sep 2011
Seed Round Undisclosed 1
Imprimatur Capital
Imprimatur Capital
01 Sep 2009

TheraCryf Alternatives & Competitors

View All Alternatives
TheraCryf vs
Sling Therapeutics
Sling Therapeutics United States

Focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease...

Series A
12 employees
Biopharma, Biotechnology
TheraCryf vs
Prelude Therapeutics
Prelude Therapeutics United States

Precision Oncology, Redefined.

Post-IPO Equity
126 employees
Biopharma, Biotechnology
TheraCryf vs
Emalex Biosciences
Emalex Biosciences United States

Improving people's lives impacted by central nervous system disorders through meaningful scientific...

Series D
54 employees
Biopharma, Biotechnology
View all alternatives

FAQ About TheraCryf

TheraCryf plc is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf’s strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma. Formerly Evgen...
TheraCryf was founded in 2007.
TheraCryf is headquartered in Wilmslow, United Kingdom.
TheraCryf operates in Biotechnology and Pharmaceutical. Its work centres on Clinical stage drug development, Cancer treatment, Neurological disease treatment and Sulforadex® technology. Its customers include Mid-size to Large Pharmaceutical Companies, Patients with Brain Disorders and Healthcare Providers.
TheraCryf has a B2B and B2D business model. Its revenue comes from Licensing, Performance Based and Product Sales.
TheraCryf has approximately 9 employees.
TheraCryf has completed 5 funding rounds, raising a total of $12.46M. The latest funding stage is Post-IPO Equity.
TheraCryf offers: Drug Discovery, Pre-clinical Development, Clinical Collaboration, Regulatory Submissions.
Top alternatives and competitors to TheraCryf include Sling Therapeutics, Prelude Therapeutics, Emalex Biosciences, ROME Therapeutics, Insilico Medicine. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
TheraCryf and Sling Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for TheraCryf, https://bouncewatch.com/company/evgen-pharma, updated 11 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes